24MAY

CEPI rescues Moderna H5N1 vaccine trial

2 min read

16:06UTC

CEPI committed $54.3m to keep Moderna's Phase 3 mRNA H5N1 vaccine trial alive after the US health department scrapped its funding.

← Back to Ebola triples, response misfires Jump to analysis ↓

ScienceDeveloping

Key takeaway

CEPI is now funding the leading bird-flu vaccine trial that US federal money abandoned mid-stream.

The Coalition for Epidemic Preparedness Innovations (CEPI) committed $54.3 million to keep alive Moderna's Phase 3 trial of its messenger-RNA (mRNA) H5N1 vaccine after the US Department of Health and Human Services scrapped the federal funding ¹. First participants were dosed on 21 April , and the candidate, mRNA-1018, is the furthest any mRNA H5N1 vaccine has reached ². H5N1 is the avian influenza strain whose spread through dairy cattle and poultry has kept pandemic planners watching.

The rescue is the same retreat-and-backstop pattern visible at the US border and in the thinned-out Ituri response: a US withdrawal from a pandemic-preparedness commitment, absorbed by a multilateral body. CEPI did not fund this trial originally; it stepped into a gap created by a policy decision, which leaves the world's leading bird-flu vaccine candidate dependent on whoever is willing to cover the cost after the largest single funder leaves.

Deep Analysis

In plain English

H5N1 is the bird flu strain that has been spreading in US dairy cattle since 2024. Scientists have long worried that if it mutates to spread easily between people, it could cause a severe pandemic. Moderna, a US vaccine company, developed an mRNA-based H5N1 vaccine candidate called mRNA-1018 using the same technology platform as the Covid-19 vaccines. It is now in Phase 3, the large-scale human trial that tests whether a vaccine is safe and effective before it can be approved. CEPI, the Coalition for Epidemic Preparedness Innovations (a global partnership funded by governments and charities), committed $54.3 million to keep the trial running after the US government's health department pulled its funding. First participants were dosed on 21 April 2026. This trial matters because if H5N1 did cause a human pandemic, an already-tested mRNA vaccine could be adapted and produced far faster than a traditional egg-based vaccine.

Source Landscape

This story draws on neutral-leaning sources

Consensus view: CEPI's 100 Days Mission framework, which aims to have a vaccine in Phase 3 trial within 100 days of a declared pandemic threat, is being tested in real time by the mRNA-1018 commitment: CEPI's $54.3 million fills the gap left by HHS withdrawing US government funding, but the dependency is now on a single Coalition funder rather than the distributed public-private architecture that produced COVID-19 vaccines at speed.

First dosing on 21 April and Phase 3 continuation to completion represents the furthest any mRNA H5N1 candidate has reached.

Counter-view: The Pasteur Network's regulatory capacity programme, which CEPI expanded via a 21 April 2026 partnership , argued that the mRNA-1018 trial's value is contingent on regulatory capacity in potential pandemic-affected countries: if H5N1 achieves efficient human-to-human transmission in Southeast Asia or Latin America, those countries' regulatory agencies would need expedited review pathways to authorise the vaccine for emergency use.

Those pathways still do not exist in most middle-income countries, regardless of how fast CEPI can manufacture doses.

Key tension: Whether a Phase 3 trial result obtained under CEPI funding, without US government co-ownership, can be leveraged into rapid FDA Emergency Use Authorisation and simultaneous WHO Emergency Use Listing: the two regulatory gates that would determine actual deployment speed in a pandemic.

Sources:Coalition for Epidemic Preparedness Innovations

Mentions:CEPI →Moderna →H5N1 →United States →Phase 3 →Pasteur Network →Coalition →Washington →World Health Organization →

First Reported In

Update #4 · Ebola triples, response misfires

Coalition for Epidemic Preparedness Innovations· 24 May 2026

Read original →

Causes and effects

Caused by

Moderna begins Phase 3 H5N1 mRNA trial

CEPI's $54.3m commitment rescues the Moderna Phase 3 trial that began dosing on 22 April after CEPI's original announcement.

Occurred 22 Apr 2026

Read story →

This Event

CEPI rescues Moderna H5N1 vaccine trial

A multilateral coalition is now financing the furthest-advanced bird-flu vaccine that Washington walked away from.

Different Perspectives

European Union / ECDC

ECDC activated an EU Health Task Force, assessed European Bundibugyo import risk as very low, and flagged the recombinant clade Ib/IIb mpox strain in four countries as a surveillance watch item. Both calls reflect the same post-2024 IHR mandate: ECDC acts as a continental early-warning layer rather than waiting for WHO Disease Outbreak News guidance.

Ituri and South Kivu communities / DRC

Residents in South Kivu torched a treatment facility when response teams arrived, a signal of community trust deficit that a no-state-apparatus response cannot overcome before it can begin. In Ituri, four healthcare worker deaths at Mongbwalu General Referral Hospital in four days reflect the population's first line of care bearing the outbreak's worst nosocomial burden without species-specific equipment or treatment.

Uganda / Diana Atwine

Atwine confirmed two imported Bundibugyo cases in Kampala with no onward spread, deployed a mobile laboratory to Kasese on the DRC border, and placed 25 contacts under monitoring before any IHR Temporary Recommendations existed. Uganda's response demonstrates that containment is achievable where a functioning state health authority can compel and protect.

Africa CDC / Jean Kaseya

Kaseya declared a continental emergency 24 hours before the WHO PHEIC and publicly opposed the US entry ban on 19 May, arguing it punishes countries by passport rather than exposure history. The declaration, Africa CDC's second consecutive pre-WHO move after the 2024 mpox sequencing, reflects an AU strategy to lead early-phase responses independently of Geneva.

United States / HHS

Washington imposed a 21-day entry ban on nationals of DRC, Uganda and South Sudan on 18 May, including green-card holders, and began enhanced screening for US citizens at George Bush Intercontinental Airport in Houston from 26 May. The ban predated WHO Temporary Recommendations by four days and covered South Sudan despite zero confirmed cases there.

Tedros Adhanom Ghebreyesus / WHO

Tedros declared the PHEIC on 17 May without the IHR Emergency Committee, then watched the committee's 22 May no-travel-restriction advice arrive four days after the US ban it was meant to prevent. A declaration without operational instructions left states parties with the headline of a global emergency but no guidance on screening, trade or deployment.